CA2484770A1 - Monoxyde de carbone servant de biomarqueur et d'agent therapeutique - Google Patents

Monoxyde de carbone servant de biomarqueur et d'agent therapeutique Download PDF

Info

Publication number
CA2484770A1
CA2484770A1 CA002484770A CA2484770A CA2484770A1 CA 2484770 A1 CA2484770 A1 CA 2484770A1 CA 002484770 A CA002484770 A CA 002484770A CA 2484770 A CA2484770 A CA 2484770A CA 2484770 A1 CA2484770 A1 CA 2484770A1
Authority
CA
Canada
Prior art keywords
carbon monoxide
patient
disease
lung
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002484770A
Other languages
English (en)
Inventor
Augustine M. K. Choi
Leo E. Otterbein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2484770A1 publication Critical patent/CA2484770A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne l'utilisation de monoxyde de carbone (CO) en tant que biomarqueur et qu'agent thérapeutique des maladies du coeur, du poumon, du foie, de la rate, du cerveau, de la peau et du rein ainsi que d'autres états et maladies pathologiques comprenant, par exemple, l'asthme, l'emphysème, la bronchite, le syndrome de détresse respiratoire de l'adulte, la sepsie, la mucoviscidose, la pneumonie, les maladies pulmonaires intersticielles, les maladies pulmonaires idiopathiques, d'autres maladies pulmonaires comprenant l'hypertension pulmonaire primaire, l'hypertension pulmonaire secondaire, les cancers, notamment le cancer du poumon, du larynx et de la gorge, l'arthrite, la cicatrisation de blessure, la maladie de Parkinson, la maladie d'Alzheimer, la maladie vasculaire périphérique et les maladies thrombotiques vasculaires pulmonaires telles que l'embolie pulmonaire. Le CO peut être utilisé pour assurer un soulagement anti-inflammatoire chez des patients souffrant de stress oxydatif et d'autres états pathologiques comprenant notamment la sepsie et le choc infectieux. De plus, le monoxyde de carbone peut être utilisé en tant que biomarqueur ou qu'agent thérapeutique pour réduire la détresse respiratoire chez des patients ayant subi une greffe pulmonaire et pour réduire ou inhiber le stress oxydatif et l'inflammation chez des greffés.
CA002484770A 2002-05-09 2002-05-09 Monoxyde de carbone servant de biomarqueur et d'agent therapeutique Abandoned CA2484770A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (fr) 2002-05-09 2002-05-09 Monoxyde de carbone servant de biomarqueur et d'agent therapeutique

Publications (1)

Publication Number Publication Date
CA2484770A1 true CA2484770A1 (fr) 2003-11-20

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002484770A Abandoned CA2484770A1 (fr) 2002-05-09 2002-05-09 Monoxyde de carbone servant de biomarqueur et d'agent therapeutique

Country Status (13)

Country Link
EP (1) EP1501523A4 (fr)
JP (1) JP2005532314A (fr)
KR (1) KR20040106515A (fr)
CN (1) CN1638781A (fr)
AU (1) AU2002308676B2 (fr)
BR (1) BR0215717A (fr)
CA (1) CA2484770A1 (fr)
EA (1) EA200401478A1 (fr)
MX (1) MXPA04011113A (fr)
NO (1) NO20044865L (fr)
RS (1) RS96904A (fr)
UA (1) UA84402C2 (fr)
WO (1) WO2003094932A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
NZ534912A (en) 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
EP1499328B1 (fr) 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methodes de traitement de l'enterocolite necrosante neonatale
PL373002A1 (en) 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
ES2372273T3 (es) * 2002-05-17 2012-01-17 Yale University Métodos de tratamiento de la hepatitis.
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
AU2007328549A1 (en) * 2006-12-06 2008-06-12 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
CA2824056C (fr) * 2011-01-14 2019-01-08 Children's Hospital Los Angeles Solution de monoxyde de carbone utilisable en vue du traitement d'une maladie, notamment la drepanocytose
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9359197B2 (en) 2011-03-24 2016-06-07 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring parkinson's disease
WO2012145520A2 (fr) 2011-04-19 2012-10-26 Alfama, Inc. Molécules libérant du monoxyde de carbone et utilisations de celles-ci
EP2734235B1 (fr) 2011-07-21 2017-03-22 Alfama, Inc. Molécules libérant du ruthénium-monoxyde de carbone et utilisations de celles-ci
US10031126B2 (en) 2013-04-04 2018-07-24 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (fr) * 2013-11-04 2015-05-06 Universität Zürich Composés à libération de monoxide de carbone et leurs formulations utiles pour induire la biogenèse mitochondriale et la réparation tissulaire
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
JP7396597B2 (ja) 2018-06-08 2023-12-12 住友精化株式会社 炎症性消化器官疾患用組成物
WO2019235166A1 (fr) * 2018-06-08 2019-12-12 住友精化株式会社 Composition pour le traitement de plaies cutanées
US20220296636A1 (en) * 2019-06-06 2022-09-22 The General Hospital Corporation Carbon Monoxide as a Treatment for Neurodegenerative Disease
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
ATE253372T1 (de) * 1996-08-27 2003-11-15 Messer Griesheim Gmbh Wasserstoffhaltiges medikament
WO2002078684A2 (fr) * 2001-03-30 2002-10-10 Sangstat Medical Corporation Composes generateurs de monoxyde de carbone pour le traitement de troubles vasculaires, inflammatoires et immunitaires

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods

Also Published As

Publication number Publication date
AU2002308676B2 (en) 2009-06-11
UA84402C2 (ru) 2008-10-27
AU2002308676A1 (en) 2003-11-11
NO20044865L (no) 2004-12-07
WO2003094932A1 (fr) 2003-11-20
CN1638781A (zh) 2005-07-13
RS96904A (en) 2007-02-05
EP1501523A1 (fr) 2005-02-02
KR20040106515A (ko) 2004-12-17
MXPA04011113A (es) 2005-02-14
EP1501523A4 (fr) 2006-12-13
BR0215717A (pt) 2005-02-22
JP2005532314A (ja) 2005-10-27
EA200401478A1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
AU2002308676B2 (en) Carbon monoxide as a biomarker and therapeutic agent
US20040228930A1 (en) Treatment for hemorrhagic shock
US7678390B2 (en) Carbon monoxide as a biomarker and therapeutic agent
EP1499328B1 (fr) Methodes de traitement de l'enterocolite necrosante neonatale
US20040258772A1 (en) Methods of treating angiogenesis, tumor growth, and metastasis
ES2546280T3 (es) Monóxido de carbono para su uso en un método para tratar íleo
Fullerton et al. Inhaled nitric oxide: therapeutic applications in cardiothoracic surgery
US20170165293A1 (en) Method and apparatus for scavenging plasma free hemoglobin
US9421222B2 (en) Treatment of compartment syndrome
US8778413B2 (en) Dosing regimens and methods of treatment using carbon monoxide
Tomita et al. Nitric Oxide and Respiratory Diseases
Exacerbates laboratory and animal investigations

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued